Leading ignition interlock provider becomes Gold Sponsor of the Florida Association of Criminal Defense Lawyers as part of a broader push to support DUI recovery and reduce impaired driving statewide.

Key Takeaways

Intoxalock is now a Gold Sponsor of the Florida Association of Criminal Defense Lawyers (FACDL).The partnership supports education and resources for Florida attorneys helping clients navigate DUI requirements and recovery.Intoxalock and Mindr provide services spanning ignition interlock, FR-44 insurance and ongoing alcohol accountability.

MIAMI, Aug. 24, 2026 /PRNewswire/ — Mindr’s brand Intoxalock, the nation’s leading ignition interlock device provider, today announced it has become a Gold Sponsor of the Florida Association of Criminal Defense Lawyers (FACDL). The partnership centers on empowering defense attorneys with the education and tools needed to assist clients, helping them safely navigate the legal and recovery process and successfully rebuild their lives after a DUI charge.

DUI offenses often stem from complex personal challenges, and recovering from a DUI charge requires a strong support system. According to the Centers for Disease Control and Prevention (CDC), the average drunk driver gets behind the wheel roughly 80 times before their first arrest.

Intoxalock’s ignition interlock devices (IIDs) serve as a proven, highly effective bridge back to safe driving. According to Mothers Against Drunk Driving (MADD), in-car breathalyzers have stopped more than 5.7 million drunk driving attempts nationally since 2006. Research shows that interlocks reduce recidivism, making drivers up to 75% less likely to reoffend than those without a device. Furthermore, states maximizing IID usage across all DUI offenses have seen up to 26% fewer fatal crashes.

Intoxalock’s sponsorship is designed to support the legal defense community, treatment court programs, and individuals in closing that gap in the state. By doing this, Intoxalock is fostering true accountability while providing a clear path back to driving and daily routines.

FACDL is the only statewide organization dedicated exclusively to the criminal defense bar, serving over 1,000 members, including private practitioners, public defenders, law students, and affiliate partners. As a Gold Sponsor, Intoxalock provides resources through FACDL’s continuing legal education programs, helping attorneys navigate state-mandated ignition interlock requirements, insurance nuances, and recovery options for their clients.

“Most people who enter the legal system following a DUI are looking for a path forward,” said Kathleen Donnelly, East Coast Manager for Intoxalock. “Attorneys are often the first source of guidance for someone who made a significant mistake and wants to take responsibility. Our goal with this sponsorship is to directly support defense attorneys with the tools and resources they need to help their clients complete their programs, maintain their livelihood and regain their independence safely.”

Through its parent company, Mindr, Intoxalock is the only ignition interlock company that collaborates with sister brands to support individuals through every stage of their recovery journey. This holistic approach to the DUI process includes Breathe Easy Insurance, which aids individuals in meeting Florida’s state-mandated FR-44 insurance requirements, and Keepr, a portable personal breathalyzer and app designed to support smarter choices even outside of a vehicle by encouraging personal accountability both during and after program completion.

With new FACDL leadership welcoming closer collaboration, the sponsorship opens the door to stronger community-focused legal education across Florida.

“We are mission-focused on helping people and communities stay safe,” Donnelly added. “By offering holistic and comprehensive services in Florida with Intoxalock, Breathe Easy Insurance and Keepr, our focus is on supporting people at every stage of their journey, from initial installation through program graduation and beyond. We are grateful to FACDL’s leadership for this opportunity to collaborate, educate and work alongside the defense bar to help people move forward responsibly.”

About Intoxalock 

Intoxalock is the leading ignition interlock brand in the U.S. and a trusted partner to individuals, affiliates, and the state monitoring authorities. Intoxalock has nearly 6,000 service centers across the country and locations within 15 miles of 90% of its customers.

Initially launched in 1988 with the first IID to use fuel cell technology, Intoxalock exists to help drivers meet legal requirements and regain driving privileges quickly and confidently. The company has helped more than 1.2 million people work toward regaining driving privileges. 

With nearly four decades of experience, Intoxalock’s knowledgeable experts help customers get back on the road safely and quickly. Intoxalock is part of Mindr’s portfolio of substance detection, monitoring, and safety solutions. 

To learn more about Intoxalock, visit www.intoxalock.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/intoxalock-expands-investment-in-florida-criminal-defense-group-to-support-dui-recovery-and-rehabilitation-in-the-state-302858412.html

SOURCE Intoxalock

Second-quarter revenue totaled RMB19.74 billion. Quarterly gross margin reached 20.7%.Overseas deliveries surpassed 20,000 units in Q2, with overseas markets contributing 25% of H1 revenue.Robotics business raises over US$900 million, at a post-money valuation of over US$6.3 billion, marking the largest single-round private financing ever recorded in China’s embodied AI industry.XPENG L03 secures historic order volume at launch, with oversea deliveries of L03 expected to start in Q4, driving the company’s quarterly overseas deliveries to exceed 40,000 units.

GUANGZHOU, China, Aug. 24, 2026 /PRNewswire/ — XPENG, a leading global Physical AI company, today announced its financial results for the second quarter of 2026. 

Physical AI Commercialization Accelerates: Robotics business raises over US$900 million, VLA 2.0 Model First Major Upgrade.

During the earnings call, He Xiaopeng, Chairman and CEO, detailed the company’s ongoing transformation into a global leader in the physical AI world.

Humanoid Robot: XPENG Robotics business raises over US$900 million, at a post-money valuation of over US$6.3 billion, marking the largest single-round private financing ever recorded in China’s embodied AI industry. Recently, XPENG’s IRON humanoid robot has reached multiple R&D milestones and is about to release capability previews. In 2027, XPENG IRON will officially launch and begin large-scale deliveries in China and overseas to external customers in the retail and service sectors. Monthly production capacity can be rapidly ramped up to several thousand units by 2027 in response to market demand.ADAS: Starting at the end of August, XPENG’s VLA 2.0 model will undergo its first major upgrade in China. The new version will also integrate VLA and VLM models to achieve integrated cockpit and autonomous driving functionality, bringing selected L4-level capabilities developed for XPENG Robotaxi to passenger vehicles. The goal is to obtain regulatory approval in Europe first in the first half of 2027 and begin deliveries to overseas users.Robotaxi: Mass-produced Robotaxi powered by VLA 2.0 has completed more than 2,000 internal test orders in Guangzhou and validated the full end-to-end process for trial passenger operations. Our goal is to achieve passenger-carrying operations without a safety driver by 2027.

Overseas Market Enters High-Growth Trajectory, Contributes over 25% of H1 Revenue

Mr. He emphasized that despite industry-wide cost pressures, operations have remained resilient. Driven by key breakthroughs in premiumization and overseas markets, gross margin surpassed 20.7% in Q2.

In Q2, XPENG’s overseas deliveries surpassed 20,000 units for the first time, up 81% year-over-year. In H1 2026, overseas business contributed over 25% of total revenue. The average selling price exceeded €40,000, with per-vehicle revenue and gross profit at the forefront of Chinese automakers expanding globally.

In July, the GX delivered over 7,000 units in the domestic market, making it one of the top-three models in China’s NEV SUV segment priced above RMB300,000.

The flagship SUV G9L will officially launch and begin deliveries in China in September. XPENG L03, as the Next-Gen AI SUV Coupe, became a phenomenal hit after its launch, with orders breaking new records for XPENG’s entire lineup. Overseas deliveries of the L03 are expected to begin in Q4, driving firmwide quarterly overseas deliveries to exceed 40,000 units.

To accelerate the commercialization of physical AI, XPENG has recently established a group-level strategic BD team, engaging with partners both domestically and overseas to bring Turing AI chips, NGP, Robotaxi and humanoid robot technologies to global markets.

About XPENG

XPENG is a leading global Physical AI company, dedicated to bringing artificial intelligence into the physical world to reshape future mobility and smart living. Through in-house R&D, XPENG has developed a full-stack Physical AI architecture spanning Turing AI chips, world foundation models, and highly integrated software and hardware applications. This unified technology foundation of XPENG powers an expansive product portfolio of smart EVs, robotaxis, and humanoid robots, advancing the deployment of Physical AI at scale. Headquartered in Guangzhou, China, XPENG is dual-primary listed on the New York Stock Exchange and the Hong Kong Stock Exchange. With global capabilities across R&D, manufacturing, sales, and services, XPENG drives continuous technological innovation and fosters an open Physical AI ecosystem, making life smarter, safer, and better for users worldwide. For more information, please visit https://www.xpeng.com/.

For media inquiries:
XPENG PR Department
Email: pr@xiaopeng.com 

View original content:https://www.prnewswire.com/news-releases/xpeng-reports-q2-2026-results-gross-margin-reaches-20-7-overseas-market-drives-25-of-h1-revenue-302858419.html

SOURCE XPENG

First commercial deployment of FDB Script Agent™ with Tebra converts ambient encounter dialogue into structured prescriptions for clinician review, grounded in trusted medication intelligence

SOUTH SAN FRANCISCO, Calif., Aug. 24, 2026 /PRNewswire/ — FDB (First Databank, Inc.), the leading provider of clinically robust, AI-enabled medication intelligence that helps healthcare professionals make precise medication decisions and streamline medication workflows, today announced the first commercial deployment of FDB Script Agent™, an AI prescribing agent that turns patient-visit dialogue into structured prescriptions ready for clinician review. The deployment with Tebra, an all-in-one technology platform for independent healthcare practices, brings FDB’s trusted medication intelligence into the ambient clinical workflow with clinical validation and terminology codification rather than simple NLP.

Script Agent uses FDB’s dose-appropriate medication intelligence to transform encounter dialogue into structured, evidence-based prescriptions for clinician review. Clinicians can modify or approve each prescription before it is sent. Due to its clinical grounding, the agent avoids hazards of simple NLP alone and will not stage prescriptions that fall outside normal prescribing practice without a clinician override.

Ambient AI has significantly reduced documentation burden by turning patient conversations into clinical notes, but prescribing often remains a manual task during or after the visit, and physician expectations are rising. FDB Script Agent extends ambient AI automation beyond documentation into prescribing by interpreting physician intent from the encounter and assembling the codified prescription elements needed by the EHR.

Tebra integrated Script Agent into its Tebra AI Note Assist, Tebra’s AI-powered clinical documentation workflow for independent ambulatory practices.

“Prescribing is one of the most important moments in care, but it still buries clinicians in administrative work,” said David Delaney, MD, president of FDB. “By capturing prescriptions directly from the ambient exam-room conversation and grounding them in FDB’s trusted medication intelligence, Script Agent turns that dialogue into a structured prescription ready for review. This lowers the administrative burden of prescribing while keeping clinicians in control.”

Early Tebra users report the AI Note Assist feature using Script Agent is intuitive and reduces prescribing-related administrative effort while preserving confidence in the review process.

“Independent practices are being asked to do more with fewer resources, and every minute spent on administrative work is time taken away from patient care,” said Kyle Ryan, Tebra chief product and technology officer. “We’re excited to partner with FDB to deliver AI-powered prescription review that simplifies prescribing workflows and reduces operational burden. These capabilities, as well as FDB’s trusted, clinically validated content, drove our decision to collaborate and help advance Tebra’s broader mission of equipping independent providers with advanced technology to make everyday healthcare operations more efficient and effective.”

Script Agent also supports FDB’s broader prescription intelligence strategy. Once a clinician approves a prescription, FDB Vela™, FDB’s cloud-native ePrescribing network, can help carry it through the next steps of the medication journey, connecting prescribers, payers, pharmacies and patients.

The Tebra deployment of Script Agent marks the first step in FDB’s broader roadmap for AI-powered prescription intelligence, designed to reduce administrative burden while keeping clinicians at the center of prescribing.

About FDB

FDB (First Databank) delivers clinically robust, AI-enabled and workflow-integrated medication intelligence that is intuitive, patient-specific, and actionable. Our solutions enable more precise medication decisions at the point of care. Trusted for our rigorous quality control, deep clinical expertise, and collaborative approach, we help improve patient safety, streamline medication workflow operations, and enhance health outcomes. Our comprehensive medication intelligence and next-generation medication decision support solutions power healthcare information systems used by the majority of hospitals, physician practices, pharmacies, payers, and beyond, impacting millions of clinicians, business associates, and patients every day. For a complete look at FDB’s solutions and services, please visit https://www.fdbhealth.com, or follow us on LinkedIn and YouTube.

About Hearst Health

The mission of Hearst Health is to guide healthcare organizations by delivering essential intelligence and software that improve the quality, safety and efficiency of care. Hearst Health has been innovating with care for more than 40 years, with a commitment to making a lasting positive impact on health. The Hearst Health companies, FDB, Homecare Homebase, MCG, MHK, QGenda and Zynx Health, elevate care by informing and empowering participants across the health journey. To learn more, visit https://www.hearst.com/hearst-health and follow @Hearst Health on LinkedIn.

About Tebra

Tebra is the only all-in-one EHR+ platform built exclusively for independent healthcare practices. Designed to replace the clunky, fragmented tools built for corporate systems, Tebra connects EHR software, billing, automation, telehealth solutions, and marketing — so providers can spend less time on admin and more time with patients. More than 42,000 private practices trust Tebra to streamline operations, increase revenue, and reduce burnout — helping clinicians leave work on time and rediscover their purpose. Learn more at www.tebra.com.

Media Contact

Supreme Communications for FDB

FDBPR@supremecomms.ai

View original content to download multimedia:https://www.prnewswire.com/news-releases/fdb-moves-ambient-listening-beyond-notes-with-ai-powered-prescribing-agent-302858338.html

SOURCE FDB (First Databank)